Abstract 4874: Receptor pharmacology and anti-cancer activity of selective DRD2/3 antagonist imipridone ONC206
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4874
Abstract: Dopamine receptor D2 (DRD2) is a G protein-coupled receptor (GPCR) overexpressed in many cancers and its antagonism causes anti-tumor effects. ONC201, founding member of the imipridone class of small molecules, is a DRD2 antagonist in… read more here.
Keywords: pharmacology; drd2; drd2 antagonist; cancer ... See more keywords
Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.5592
Abstract: 5592Background: mEC is a generally incurable, with limited therapeutic options. ONC201 is the founding member of the new class of compounds called imipridones that are orally active small molecules... read more here.
Keywords: onc201 imipridone; clinical activity; antagonist onc201; selective drd2 ... See more keywords